Clinical Trials
231
18 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1868
Active, not recruiting
10
4.3%
Completed
127
55.0%
Enrolling By Invitation
2
0.9%
Not yet recruiting
6
2.6%
Recruiting
28
12.1%
Terminated
10
4.3%
Unknown
36
15.6%
Withdrawn
12
5.2%
No approval data available
- The NIH NIAID has awarded a five-year, $2.4 million R01 grant to Dr. Jiahui Ding at Wayne State University to study how maternal viral infections during pregnancy shape lifelong immune health in offspring. - The research focuses on the placenta as a key mediator, examining how placental inflammasome activation and IL-1β signaling reprogram fetal hematopoietic stem cells in a sex-dimorphic manner. - Preliminary findings indicate maternal viral infection impairs neutrophil function and increases inflammatory sensitivity predominantly in male offspring, suggesting sex-specific placental inflammatory pathways. - The project employs cutting-edge approaches including single-cell transcriptomics, epigenetic profiling, and an innovative human placenta–fetal interface organ-on-chip model.
- DB-1311/BNT324, a novel B7H3-targeted antibody-drug conjugate, demonstrated a 42.4% overall response rate in previously treated cervical cancer patients with a median progression-free survival of 7.0 months. - In platinum-resistant ovarian cancer patients, the ADC achieved a 53.3% overall response rate and 9.5 months median progression-free survival, showing efficacy regardless of prior treatment history. - The treatment showed consistent activity across different histological subtypes and prior therapy lines, with manageable safety profile and low treatment discontinuation rates. - Grade 3 or higher treatment-related adverse events occurred in 54.1% of patients, with dose reductions needed in 27% of cervical cancer patients and treatment discontinuation due to adverse events in only 2.7% of cases.
- Advanced systemic therapies, particularly biologics, have revolutionized psoriasis treatment for over 8 million Americans, offering highly effective options with favorable safety profiles compared to historical treatments like phototherapy and methotrexate. - Despite therapeutic advances, significant access barriers persist including insurance coverage limitations, high out-of-pocket costs, and prior authorization requirements, with cost identified as the biggest treatment hurdle by dermatologists. - The psychological impact of psoriasis extends far beyond visible symptoms, with patients experiencing 1.5 times higher depression rates and anxiety affecting up to half of diagnosed individuals. - Patient-centered care approaches now emphasize individualized treatment selection based on disease severity, comorbidities, and patient preferences, moving away from standardized treatment ladders.
- UCLA-led researchers received a $3.5 million NIH grant to develop treatments for mpox, focusing on a more virulent strain causing increased deaths among children in the Democratic Republic of Congo. - The team has identified promising drug candidates that restore the STING immune pathway, which newer mpox strains have evolved to suppress, successfully blocking viral replication in mouse models without toxicity. - The research will advance to human tissue models using stem cell-derived skin organoids and eye tissue, with hopes to approach the FDA for clinical trial discussions next year.
- Wayne State University enrolled the first Michigan patient in a Phase I/II trial testing stem cell-derived interneuron implantation to reduce seizure frequency. - The trial, "A First-In-Human Study of Inhibitory Interneurons (NRTX-1001)," targets drug-resistant unilateral mesial temporal lobe epilepsy (MTLE). - The six-hour procedure involves robotic and stereotactic techniques to deliver GABA-secreting cells into the hippocampus, aiming for a 75% seizure reduction. - The study will assess safety, tolerability, cell viability, inflammation, and effects on epilepsy symptoms over two years, with a 13-year follow-up.
